Biotech: Page 2
-
Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease
New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.
By Michael Gibney • Dec. 22, 2022 -
Podcast
Woman of the Week: Exelixis’ Dr. Vicki Goodman
With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.
By Taren Grom • Dec. 14, 2022 -
Tracker
The 2023 PharmaVoice Year in Preview
Here’s a look at how industry leaders are navigating the key issues of 2023.
Dec. 12, 2022 -
With FDA filing on the horizon, Karuna appoints new CEO
Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.
By Karissa Waddick • Dec. 9, 2022 -
Q&A
For Duchenne-focused Sarepta, gene therapy is the natural next step
The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.
By Michael Gibney • Dec. 8, 2022 -
10 noteworthy pharma leadership shake-ups this year
From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.
By Karissa Waddick • Dec. 7, 2022 -
Podcast
Woman of the Week: Simcha Therapeutics’ Beatrice McQueen
From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.
By Taren Grom • Dec. 7, 2022 -
Q&A
A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
Opinion
Healthcare tech’s biggest busts
The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.
By Taren Grom • Dec. 2, 2022 -
5 final FDA action dates to watch this year
A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.
By Michael Gibney • Dec. 1, 2022 -
10 of our most popular articles in 2022
Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.
By Meagan Parrish • Nov. 30, 2022 -
Podcast
Woman of the Week: Surface Oncology’s Dr. Alison O’Neill
With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.
By Taren Grom • Nov. 30, 2022 -
One biotech’s approach to science-driven innovation
Why some in the industry say fostering creativity in drug development is all about work structures.
By Karissa Waddick • Nov. 29, 2022 -
Q&A // Biotech Spotlight
Evommune’s unique method of drug discovery is more than skin deep
The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.
By Michael Gibney • Nov. 29, 2022 -
Avoiding a ‘bad trip’ in psychedelic clinical trials
Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.
By Kelly Bilodeau • Nov. 28, 2022 -
Podcast
Woman of the Week: Myriad Genetics’ Nicole Lambert
Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.
By Taren Grom • Nov. 23, 2022 -
The next era of Greater Boston’s biotech boom
How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.
By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022 -
Profile
How bacteria-enabled technology for wounds could also help cancer patients
Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.
By Alexandra Pecci • Nov. 22, 2022 -
Q&A
In cancers with very low survival rates, Sellas aims higher
The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.
By Kelly Bilodeau • Nov. 21, 2022 -
Why the biopharma ‘IPO playbook’ changed in 2022
Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.
By Michael Gibney • Nov. 21, 2022 -
Sponsored by ClinicalMind
Can a formal needs assessment simplify Speaker Bureau compliance?
In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.
Nov. 21, 2022 -
Is AI just hype or a real revolution in pharma? It’s complicated
Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.
By Michael Gibney • Nov. 17, 2022 -
To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’
A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.
By Michael Gibney • Nov. 16, 2022 -
#HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market
Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.
By Meagan Parrish • Nov. 15, 2022 -
Profile
A ‘bold vision’ to prevent diabetes
Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts.
By Alexandra Pecci • Nov. 15, 2022